DrugPatentWatch Database Preview

VIIBRYD Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Allergan Sales Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-two patent family members in thirty-two countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

Summary for VIIBRYD

International Patents:	92
US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	60
Clinical Trials:	16
Patent Applications:	35
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for VIIBRYD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIIBRYD
DailyMed Link:	VIIBRYD at DailyMed

Generic Entry Opportunity Date for VIIBRYD

NDA:

022567

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for VIIBRYD

Antidepressive Agents

Serotonin 5-HT1 Receptor Agonists

Serotonin Uptake Inhibitors

Synonyms for VIIBRYD

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride

1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride

163521-08-2

2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1)

2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride

2794AH

4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride

5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride

5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride

5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride

5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride

5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide hydrochloride

5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride

5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride

5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride

5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride

521V128

AB0000947

AC-25885

AC1OCFA0

AK161007

AKOS024464039

AN-5344

API0009252

AX8294006

C26H27N5O2.ClH

CCG-213313

CHEBI:70705

CHEMBL1615374

CS-0549

D09699

EBD2199528

EMD 68 843

EMD 68843

EMD-68-843

EMD-68843

EMD68843

HE069874

HY-14261

J-525160

KB-81444

KS-00000SKE

LS-34922

MFCD00940014

MolPort-028-744-909

RL02096

RL02097

RPZBRGFNBNQSOP-UHFFFAOYSA-N

s4259

SB 659746A

SB-659746-A

SB-659746A

SB659746-A

SB659746A

SCHEMBL867358

ST24050347

U8HTX2GK8J

UNII-U8HTX2GK8J

Viibryd (TN)

Vilazodone (Hydrochloride)

Vilazodone HCl

Vilazodone hydrochloride

Vilazodone hydrochloride (USAN)

Vilazodone hydrochloride [USAN]

Vilazodone Hydrochloride 1.0 mg/ml in Methanol (as free base)

Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Vilazodone hydrochloride, >=98% (HPLC)

vilazodone monohydrochloride

Vilazodonei

US Patents and Regulatory Information for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011		RX	Yes	Yes			Y	Y
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011		RX	Yes	No
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011		RX	Yes	No			Y	Y
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011		RX	Yes	Yes			Y	Y
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011		RX	Yes	No
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011		RX	Yes	No
Allergan Sales Llc	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011		RX	Yes	No			Y	Y

  Purchase this report

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for VIIBRYD

Drugname	Dosage	Strength	RLD	Date
	Tablets	10 mg, 20 mg, and 40 mg

Non-Orange Book US Patents for VIIBRYD

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,381,726	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
8,927,552	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
8,318,744	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
7,981,894	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
8,921,375	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
9,624,204	Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride

  Purchase this report

see a sample report or, see our see our flat-rate plans

International Patents for VIIBRYD

Country	Document Number	Estimated Expiration
Canada	2782865
Canada	2782615
Germany	59402902
Argentina	034595
Hungary	T71833
Canada	2782494
Russian Federation	2132848